NCT06629103

A Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA

A Randomized, Double-blind Placebo-controlled Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA From Two Microalgal Sources to One Fish Source

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: RDC Clinical Pty Ltd · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

This is a randomised, double-blind, parallel, placebo-controlled study in healthy subjects to compare the absorption of two microalgal formulations, to a fish oil and a placebo.

Conditions

• Optimal Absorption of Omega-3
• Healthy

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	life's Omega 1035DS	A natural triglyceride derived from microalgae with minimum 365 mg DHA, minimum 100 mg EPA, and minimum 520 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.
DIETARY_SUPPLEMENT	Fish Oil	Commercially available fish oil product MEG-3 1812 TG with a minimum 100 mg DHA/capsule, minimum 160 mg EPA/capsule, and minimum 300 mg/g DHA+EPA. Participants receive 600mg/d of omega-3 fatty acids from the fish oil.
OTHER	Placebo	The placebo capsules will be a mixture of corn and soybean oils. Participants receive 600mg/d of omega-3 fatty acids from the corn/soy placebo.
DIETARY_SUPPLEMENT	life's Omega O3020DS	A natural triglyceride derived from microalgae with minimum 210 mg DHA, minimum 300 mg EPA, and minimum 510 mg/g DHA + EPA. Participants receive 600mg/d of omega-3 fatty acids from the microalgal oil.

Timeline

• Start date: 2025-08-06
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2024-10-08
• Last updated: 2025-11-18

Locations

1 site across 1 country: Australia